HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gucci Q2

This article was originally published in The Rose Sheet

Executive Summary

Yves Saint Laurent fragrance and cosmetics sales increased 5.7% on constant currency basis for fiscal second quarter ended July 31, Gucci announces in 1sales and earnings report Sept. 26. Sales were fueled by strong growth of Opium, which saw a 23.6% increase in sales during the period, company adds. Despite strength of Yves Saint Laurent, YSL Beauté consolidated sales fell 3.8% during the quarter to $104.4 mil. (€1=$.98). Beauty division still on track to achieve high single-digit revenue growth and operating margin before goodwill and trademark amortization of approximately 7%, Gucci maintains...

You may also be interested in...



Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds

First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.

Unfairly Hit By Influencer Assassins? Now Could Be Your Chance To Mobilize The FTC

Brands unfairly attacked by powerful influencers could raise the subject with the US Federal Trade Commission, which is asking for comments on its “Endorsement Guides."  

UsernamePublicRestriction

Register

RS010649

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel